Compare · TMDX vs VANI
TMDX vs VANI
Side-by-side comparison of TransMedics Group Inc. (TMDX) and Vivani Medical Inc. (VANI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TMDX and VANI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $3.25B, about 25.3x VANI ($128.1M).
- Over the past year, TMDX is down 18.7% and VANI is up 17.4% - VANI leads by 36.1 points.
- VANI has been more active in the news (7 items in the past 4 weeks vs 5 for TMDX).
- TMDX has more recent analyst coverage (19 ratings vs 0 for VANI).
- Company
- TransMedics Group Inc.
- Vivani Medical Inc.
- Price
- $93.68+0.10%
- $1.42+3.27%
- Market cap
- $3.25B
- $128.1M
- 1M return
- +25.93%
- +9.23%
- 1Y return
- -18.71%
- +17.36%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2014
- News (4w)
- 5
- 7
- Recent ratings
- 19
- 0
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest TMDX
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
- UBS initiated coverage on TransMedics Group with a new price target
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)
Latest VANI
- Vivani Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Vivani Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
- SEC Form 10-Q filed by Vivani Medical Inc.
- Why Investors Are Watching These Healthcare Movers
- Vivani Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
- SEC Form 4 filed by Chief Business Officer Dwyer Donald
- SEC Form 4 filed by Chief Medical Officer Porter Lisa Ellen
- SEC Form 4 filed by Chief Financial Officer Baldor Anthony